Saturday 17 October 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024. In the quarter to June 2026, revenue grew 25.7%, EPS grew 19.5% and free cash flow fell 4.95%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
117.81
17.65
−13.03%
Follow GRAL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.81 | 13.45 | 21.37 | 15.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(36.46) | (24.14) | (49.32) | (33.77) | |
P/B ratio |
1.16 | 0.84 | 1.22 | 0.95 | |
Price to Tangible BV |
3.87 | 3.07 | 4.33 | 6.02 | |
EV/Sales |
12.60 | 8.18 | 15.23 | 11.25 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.06) | (4.39) | (7.50) | (4.85) | |
EV/FCF |
(7.03) | (4.37) | (7.47) | (4.84) | |
Quick Ratio |
10.55 | 11.29 | 11.58 | 7.19 | |
Current Ratio |
10.95 | 11.74 | 11.97 | 7.61 | |
Net Debt/EBITDA |
7.44 | 7.95 | 10.04 | 5.93 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.06 | 0.05 | 0.05 | |
Operating CF/Net income |
0.73 | 0.93 | 0.64 | 0.71 | |
Capex/Depreciation |
(0.01) | (0.02) | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
106.14% | 117.74% | 107.57% | 134.41% | |
Selling, General and Administrative Expense of Revenue |
197.74% | 180.06% | 152.26% | 173.82% | |
Intangible Assets out of Total Assets |
0.63 | 0.65 | 0.63 | 0.72 | |
Share Based Compensation of Revenue |
43.76% | 41.17% | 31.57% | 39.06% | |
Graham Net Nets |
0.21 | 0.27 | 0.19 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.28%) | (20.07%) | (13.06%) | (19.67%) | |
Free Cash Flow Yield |
(10.06%) | (13.92%) | (9.53%) | (15.44%) | |
Revenue per Share |
1.04 | 1.00 | 1.19 | 1.00 | |
Operating CF per Share |
(1.87) | (2.14) | (1.74) | (1.75) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(1.88) | (2.15) | (1.74) | (1.76) | |
Cash per Share |
19.98 | 20.25 | 24.61 | 14.95 | |
Shareholders Equity per Share |
58.98 | 61.53 | 70.14 | 62.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
58.98 | 61.53 | 70.14 | 62.01 | |
Free Cash Flow |
(81.16) | (87.49) | (63.88) | (63.63) | |
Working Capital |
831.18 | 802.64 | 874.18 | 511.95 | |
Capital Expenditures |
(0.43) | (0.50) | (0.09) | (0.38) | |
Net Current Asset Value |
613.69 | 574.56 | 609.70 | 228.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.04 | 19.83 | 19.30 | 15.75 | |
Average Payables |
6.76 | 5.22 | 3.46 | 5.36 | |
Average Assets |
2,773.12 | 2,825.54 | 2,952.66 | 2,859.49 | |
Average Common Equity |
2,428.65 | 2,457.18 | 2,540.63 | 2,413.80 |
Columns are period end dates